Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
KYORIN Pharmaceutical Co.,Ltd. ( (JP:4569) ) has issued an update.
KYORIN Pharmaceutical has signed an exclusive distribution and promotion agreement in Japan with Johnson & Johnson’s Janssen unit for SIRTURO, an oral diarylquinoline antimycobacterial drug already marketed domestically as part of combination therapy for multidrug-resistant pulmonary tuberculosis. Under the deal, KYORIN will assume sole promotional activities from June 2026, and, once additional approval is obtained for treatment-refractory Mycobacterium avium complex-lung disease, it will also exclusively distribute SIRTURO, reinforcing its infectious disease franchise with limited impact expected on current fiscal earnings.
The partnership allows KYORIN to deepen its respiratory and infectious disease portfolio by leveraging J&J’s globally marketed tuberculosis therapy, which acts by inhibiting ATP synthase in Mycobacterium tuberculosis and targets both active and dormant bacteria. While the company expects negligible effect on results for the year ending March 31, 2026, the agreement aligns with its medium-term plan to grow through in-licensing in specialized fields, offering potential longer-term benefits for patients with difficult-to-treat mycobacterial lung diseases and supporting KYORIN’s positioning in niche therapeutic areas.
The most recent analyst rating on (JP:4569) stock is a Hold with a Yen1693.00 price target. To see the full list of analyst forecasts on KYORIN Pharmaceutical Co.,Ltd. stock, see the JP:4569 Stock Forecast page.
More about KYORIN Pharmaceutical Co.,Ltd.
KYORIN Pharmaceutical Co., Ltd. is a Japan-based drugmaker focused on prescription pharmaceuticals, concentrating its Franchise Customer Strategy on respiratory, otolaryngology and urology fields. The company pursues growth by expanding its development pipeline through in-licensing products that can contribute to business results in the near term, while strengthening its position in treatments for infectious and respiratory diseases.
Average Trading Volume: 110,216
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen84.49B
See more insights into 4569 stock on TipRanks’ Stock Analysis page.